- Home
- SNTI vs GRFX Comparison
SNTI vs GRFX Comparison
Compare SNTI & GRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- GRFX
- Stock Information
- Founded
- SNTI 2016
- GRFX 1981
- Country
- SNTI United States
- GRFX Hong Kong
- Employees
- SNTI N/A
- GRFX N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- GRFX
- Sector
- SNTI Health Care
- GRFX
- Exchange
- SNTI Nasdaq
- GRFX Nasdaq
- Market Cap
- SNTI 17.8M
- GRFX 18.1M
- IPO Year
- SNTI N/A
- GRFX N/A
- Fundamental
- Price
- SNTI $3.20
- GRFX $1.12
- Analyst Decision
- SNTI Strong Buy
- GRFX Hold
- Analyst Count
- SNTI 1
- GRFX 1
- Target Price
- SNTI $12.00
- GRFX N/A
- AVG Volume (30 Days)
- SNTI 27.8K
- GRFX 34.9K
- Earning Date
- SNTI 05-08-2025
- GRFX 01-01-0001
- Dividend Yield
- SNTI N/A
- GRFX N/A
- EPS Growth
- SNTI N/A
- GRFX N/A
- EPS
- SNTI N/A
- GRFX N/A
- Revenue
- SNTI N/A
- GRFX $24,184,100.00
- Revenue This Year
- SNTI N/A
- GRFX N/A
- Revenue Next Year
- SNTI N/A
- GRFX N/A
- P/E Ratio
- SNTI N/A
- GRFX N/A
- Revenue Growth
- SNTI N/A
- GRFX N/A
- 52 Week Low
- SNTI $1.52
- GRFX $0.71
- 52 Week High
- SNTI $16.94
- GRFX $2.75
- Technical
- Relative Strength Index (RSI)
- SNTI 44.14
- GRFX 47.41
- Support Level
- SNTI $3.33
- GRFX $0.90
- Resistance Level
- SNTI $3.63
- GRFX $1.73
- Average True Range (ATR)
- SNTI 0.33
- GRFX 0.24
- MACD
- SNTI 0.01
- GRFX -0.00
- Stochastic Oscillator
- SNTI 25.36
- GRFX 33.13
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About GRFX Graphex Group Limited each representing 20
Graphex Group Ltd is engaged in the sale of graphene products. It operates in three segments namely, the Graphene Products Segment includes Processing and sale of graphite and graphene-related products; the Landscape Architecture Design Segment includes Providing landscape architecture design; and the catering business focuses on the operation of restaurants. The company derives the majority of its revenue from the sale of graphene products segment.